Ectonucleotide PyrophosphatasePhosphodiesterase Family Member 2 - Pipeline Review, H2 2019
Ectonucleotide PyrophosphatasePhosphodiesterase Family Member 2 - Pipeline Review, H2 2019
SUMMARY
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene. It stimulates migration of melanoma cells. It has a role in induction of parturition. It is involved in cell proliferation and adipose tissue development.
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System, Cardiovascular, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Systemic Sclerosis (Scleroderma), Breast Cancer, Inflammation, Inflammatory Bowel Disease, Lung Cancer, Multiple Sclerosis, Atherosclerosis, Chronic Obstructive Pulmonary Disease (COPD), Fibrosis, Ischemic Stroke, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Lung Cancer, Musculoskeletal Pain, Osteoarthritis Pain, Ovarian Cancer, Pain, Solid Tumor, Thyroid Cancer and Visceral Pain.
The latest report Ectonucleotide PyrophosphatasePhosphodiesterase Family Member 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene. It stimulates migration of melanoma cells. It has a role in induction of parturition. It is involved in cell proliferation and adipose tissue development.
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System, Cardiovascular, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Idiopathic Pulmonary Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Systemic Sclerosis (Scleroderma), Breast Cancer, Inflammation, Inflammatory Bowel Disease, Lung Cancer, Multiple Sclerosis, Atherosclerosis, Chronic Obstructive Pulmonary Disease (COPD), Fibrosis, Ischemic Stroke, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Lung Cancer, Musculoskeletal Pain, Osteoarthritis Pain, Ovarian Cancer, Pain, Solid Tumor, Thyroid Cancer and Visceral Pain.
The latest report Ectonucleotide PyrophosphatasePhosphodiesterase Family Member 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)
- The report reviews Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics and enlists all their major and minor projects
- The report assesses Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Overview
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Companies Involved in Therapeutics Development
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Eli Lilly and Co
Galapagos NV
iOnctura SA
LegoChem Biosciences Inc
Ono Pharmaceutical Co Ltd
PharmAkea Therapeutics Inc
Ribomic Inc
Sansho Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
X-Rx Inc
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Drug Profiles
2-CCPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBT-877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLD-0409 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLPG-1690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IOA-289 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8430506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAT-048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ATX and EGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0316 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Dormant Products
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: Galapagos completes recruitment of NOVESA trial in systemic sclerosis
Sep 29, 2019: Bridge Biotherapeutics presents positive results from phase 1 clinical study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) treatments at the ERS International Congress 2019
May 20, 2019: Bridge Biotherapeutics announces data presentation from first-in-human study of BBT-877 for idiopathic pulmonary fibrosis
Jan 24, 2019: X-Rx announces FDA acceptance of IND application for X-165
Jan 16, 2019: Bridge Biotherapeutics announces FDA Orphan Drug Designation for BBT-877 in idiopathic pulmonary fibrosis (IPF)
Jan 07, 2019: Galapagos starts Phase IIa trial of GLPG1690 for systemic sclerosis
Dec 17, 2018: Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
Dec 17, 2018: Bridge Biotherapeutics announces FDA clearance of IND for its BBT-877, an autotaxin inhibitor for IPF
Nov 18, 2018: Bridge Biotherapeutics files investigational new drug application for BBT-877, an autotaxin inhibitor for idiopathic pulmonary fibrosis
Aug 22, 2018: Bridge Biotherapeutics presented preclinical study results on BBT-877, an autotaxin inhibitor at the IPF Summit 2018
May 20, 2018: GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
Apr 12, 2018: Galapagos announces ISABELA Phase 3 program in IPF
Aug 09, 2017: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
Sep 06, 2016: Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis
Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Overview
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Companies Involved in Therapeutics Development
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Eli Lilly and Co
Galapagos NV
iOnctura SA
LegoChem Biosciences Inc
Ono Pharmaceutical Co Ltd
PharmAkea Therapeutics Inc
Ribomic Inc
Sansho Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
X-Rx Inc
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Drug Profiles
2-CCPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBT-877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLD-0409 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLPG-1690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IOA-289 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-8430506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAT-048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ATX and EGFR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Autotaxin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Autotaxin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0265 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0316 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-165 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Dormant Products
Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: Galapagos completes recruitment of NOVESA trial in systemic sclerosis
Sep 29, 2019: Bridge Biotherapeutics presents positive results from phase 1 clinical study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) treatments at the ERS International Congress 2019
May 20, 2019: Bridge Biotherapeutics announces data presentation from first-in-human study of BBT-877 for idiopathic pulmonary fibrosis
Jan 24, 2019: X-Rx announces FDA acceptance of IND application for X-165
Jan 16, 2019: Bridge Biotherapeutics announces FDA Orphan Drug Designation for BBT-877 in idiopathic pulmonary fibrosis (IPF)
Jan 07, 2019: Galapagos starts Phase IIa trial of GLPG1690 for systemic sclerosis
Dec 17, 2018: Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
Dec 17, 2018: Bridge Biotherapeutics announces FDA clearance of IND for its BBT-877, an autotaxin inhibitor for IPF
Nov 18, 2018: Bridge Biotherapeutics files investigational new drug application for BBT-877, an autotaxin inhibitor for idiopathic pulmonary fibrosis
Aug 22, 2018: Bridge Biotherapeutics presented preclinical study results on BBT-877, an autotaxin inhibitor at the IPF Summit 2018
May 20, 2018: GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS
Apr 12, 2018: Galapagos announces ISABELA Phase 3 program in IPF
Aug 09, 2017: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
Sep 06, 2016: Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis
Apr 06, 2016: Galapagos initiates a Phase 2a study with GLPG1690 in idiopathic pulmonary fibrosis patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Blade Therapeutics Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Galapagos NV, H2 2019
Pipeline by iOnctura SA, H2 2019
Pipeline by LegoChem Biosciences Inc, H2 2019
Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Pipeline by PharmAkea Therapeutics Inc, H2 2019
Pipeline by Ribomic Inc, H2 2019
Pipeline by Sansho Co Ltd, H2 2019
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2019
Pipeline by X-Rx Inc, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Blade Therapeutics Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Galapagos NV, H2 2019
Pipeline by iOnctura SA, H2 2019
Pipeline by LegoChem Biosciences Inc, H2 2019
Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
Pipeline by PharmAkea Therapeutics Inc, H2 2019
Pipeline by Ribomic Inc, H2 2019
Pipeline by Sansho Co Ltd, H2 2019
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2019
Pipeline by X-Rx Inc, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Eli Lilly and Co
Galapagos NV
iOnctura SA
LegoChem Biosciences Inc
Ono Pharmaceutical Co Ltd
PharmAkea Therapeutics Inc
Ribomic Inc
Sansho Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
X-Rx Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Blade Therapeutics Inc
Boehringer Ingelheim International GmbH
Eli Lilly and Co
Galapagos NV
iOnctura SA
LegoChem Biosciences Inc
Ono Pharmaceutical Co Ltd
PharmAkea Therapeutics Inc
Ribomic Inc
Sansho Co Ltd
TaiwanJ Pharmaceuticals Co Ltd
X-Rx Inc
